1. Academic Validation
  2. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling

FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling

  • J Biol Chem. 2005 Dec 16;280(50):41289-97. doi: 10.1074/jbc.M508221200.
Ryuichi Mashima 1 Kazuko Saeki Daisuke Aki Yasumasa Minoda Hiromi Takaki Takahito Sanada Takashi Kobayashi Hiroyuki Aburatani Yuji Yamanashi Akihiko Yoshimura
Affiliations

Affiliation

  • 1 Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Abstract

Lipopolysaccharide (LPS) activates macrophages through Toll-like Receptor (TLR) 4. Although the mechanism of the TLR signaling pathway has been well documented, the mechanism of the negative regulation in response to LPS, particularly LPS tolerance, is still poorly understood. In this study we identified and characterized a novel interferon- and LPS-inducible gene, FLN29, which contains a TRAF6-related zinc finger motif and TRAF family member-associated NF-kappaB activator-related sequences. The induction of FLN29 was dependent on STAT1. The forced expression of FLN29 in macrophage-like RAW cells resulted in the suppression of TLR-mediated NF-kappaB and mitogen-activated protein kinase activation, while a reduced expression of FLN29 by small interfering RNA partly cancelled the down-regulation of LPS signaling. Furthermore, we demonstrated that NF-kappaB activation induced by TRAF6 and TAB2 was impaired by co-expression of FLN29, suggesting FLN29 may regulate the downstream of TRAF6. Taken together, FLN29 is a new negative feedback regulator of TLR signaling.

Figures